Subscribe to Search results

By this time, self-sufficiency had largely been achieved.

Published on:

Professor Edward Tuddenham told the Inquiry that inactivation could and should have been achieved earlier.

Published on:

Christopher Bishop asserted in his oral evidence that Armour had done: "everything possible to provide the best possible treatment and the most up-to-date systems in accordance with the state of art at that time."

Published on:

Dr Peter Foster stated in his oral evidence to the Inquiry that it was difficult dealing with a possible virus, the structure of which was unknown. However, both BPL and PFC managed to inactivate NANBH before the structure of Hepatitis C was known.

Published on:

Experiments were conducted by Dr Shohachi Wada on behalf of Cutter to see if the hepatitis virus with which Factor 9 was spiked could be inactivated whilst the Fator 9 was kept active.

Published on:

Leveton and others published "HIV and the Blood Supply: An Analysis of Crisis Decisionmaking".

Published on:

Dr Edward Shanbrom, who worked as a vice-president of medical and scientific affairs at Hyland, developed the first commercially marketed freeze-dried Factor 8 concentrate. However his suggestions only attracted minimal support in the 1970s and very early 1980s.

Published on:

In Parliament, Baroness Jean Trumpington made clear that NHS products derived from screened plasma would become available for distribution during August 1986 throughout the UK.

Published on:

A surveillance of previously untreated patients for possible virus transmission by BPL Factor 8 and Factor 9 Concentrates, 8Y and 9A, was carried out in September 1986.

Published on:

BPL's work on heat treatment - regarding Factor 9 - only really started in 1982.

Published on:

The concern that heated Factor 9 concentrates might cause thrombosis was one that had to be resolved before its product could be issued. As a result experiments in dogs were conducted prior to clinical trial in humans.

Published on:

Hyland had a research project aimed at eliminating NANBH in factor concentrates that was being hindered by a lack of manpower and adequate funding.

Published on:

In February 1979 Hyland learnt of Behringwerke beginning clinical trials in 1978 in Germany on "Factor VIII Behringwerke" via a report to their head office, later confirmed by another Hyland employee.

Published on:

Hyland had heard that the clinical trials of the Behringwerke product were almost complete and had promising results.

Published on:

Hyland listed hepatitis risk removal from Hemofil as a project proposal. It noted that the removal of the risk of hepatitis transmission by Hemofil was needed in order to allow sales of the project excess inventories at the highest possible selling price.

Published on:

A letter from Dr Sternberg noted that by 1980 the research and development department of Cutter had made a strategic commitment that all new plasma products would be pasteurised.

Published on:

"The Advocate" newspaper article noted that in the early 1980s drug companies turned down a chemical process that could have prevented the infection of thousands of people with haemophilia with AIDS.

Published on:

An internal correspondence from Dr William Terry noted that due to contractual arrangements Dr Prince was precluded from publishing, without their approval, data from experiments supported by RHCG.

Published on:

The minutes of the Plasma Executive Committee noted that centres where unscreened donor product may have been delivered would not be contacted until the situation was clear.

Published on:

A memo from Dr Harris to Mr Christie outlined that on 27 February 1986 Dr Harris visited Dr Whitmore at Lewisham Hospital and followed up the history of two people with haemophilia who had seroconverted to HTLV-3 positive following treatment with heat-treated Factorate.

Published on: